Ranfoli SR 500 Tablets contain Ranolazine, a unique anti-anginal medication formulated as an extended-release tablet to ensure a sustained therapeutic effect throughout the day. Ranolazine works differently from traditional angina treatments; it improves the efficiency of the heart's metabolism without significantly affecting heart rate or blood pressure. This mechanism helps in alleviating chest pain (angina) and enhancing the patient's exercise tolerance.
Ranfoli SR 500 acts by inhibiting the late phase of the inward sodium current in heart muscle cells, which leads to a reduction in intracellular calcium levels. This relaxation of the heart muscle cells improves blood flow and oxygen delivery, thereby reducing symptoms of chronic angina. It is particularly beneficial for patients who remain symptomatic despite the use of other anti-anginal therapies.
This tablet offers the advantage of a sustained release, providing consistent plasma concentrations, minimizing dosing frequency, and enhancing patient compliance. It is often prescribed as part of a comprehensive treatment plan that includes lifestyle changes, dietary management, and other cardiovascular medications.
Manufactured with strict quality standards, Ranfoli SR 500 ensures optimal therapeutic efficacy and patient safety. It is suitable for long-term management of stable angina and is a preferred choice when first-line anti-anginal agents are not sufficient or are contraindicated.